Takeda taps Enterome for microbiome R&D

Japanese drugmaker Takeda is deepening its work in microbiomics, signing a drug discovery deal with France's Enterome Bioscience in hopes of spotlighting new treatments for gastrointestinal disorders. Under the agreement, Takeda is handing its partner an undisclosed upfront payment and promising three years of R&D funding plus milestone cash tied to the progression of drug candidates. The goal is to treat inflammatory bowel diseases and motility disorders by modulating the billions of organisms in the human gut. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.